COMPUTED DESCRIPTORS
| Molecular Weight | 1497.7 g/mol |
|---|---|
| XLogP3 | -8.9 |
| Hydrogen Bond Donor Count | 23 |
| Hydrogen Bond Acceptor Count | 34 |
| Rotatable Bond Count | 44 |
| Exact Mass | 1496.65003250 g/mol |
| Monoisotopic Mass | 1496.65003250 g/mol |
| Topological Polar Surface Area | 734 Ų |
| Heavy Atom Count | 103 |
| Formal Charge | 0 |
| Complexity | 2690 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 19 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer. It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. The development of this drug, apparently, was discontinued.